



Global Immunoassay Market: Trends, Technologies, and Growth Opportunities, 2025

SAMPLE

June 2025

© Kalorama Information

Table of Contents

| | |
|---|---------------|
| CHAPTER 1: EXECUTIVE SUMMARY | 1 |
| OVERVIEW | 1 |
| SCOPE AND METHODOLOGY | 2 |
| MARKET OVERVIEW | 4 |
| Table 1-1: Global Immunoassay Market, 2024-2029 (\$ million) [Lab-based, POC-based] | 4 |
| Figure 1-1: Global Immunoassay Market, 2024-2029 (\$ million) [Lab-based, POC-based] | 5 |
| Figure 1-2: Global Immunoassay Market Share, 2024-2029 (\$ million) [Lab-based, POC-based] | 6 |
| COMPETITIVE SUMMARY..... | 7 |
| CHAPTER 2: INTRODUCTION | 8 |
| HISTORY AND FUTURE OF IMMUNOASSAYS | 9 |
| IMMUNOASSAY TECHNOLOGY CONTINUES TO EVOLVE | 11 |
| CHAPTER 3: TECHNOLOGY, TRENDS, AND INNOVATIONS | 13 |
| OVERVIEW – IMMUNOASSAYS..... | 13 |
| Table 3-1: Immunoassay Sensitivity, by Technology Type and Setting (Lab, POC) [CLIA, ELISA, FIA, IHC, LFIA, RIA]..... | 13 |
| <i>Chemiluminescent Immunoassay (CLIA)</i> | 13 |
| <i>Enzyme-Linked Immunosorbent Assay (ELISA)</i> | 14 |
| <i>Fluoroimmunoassay (FIA)</i> | 15 |
| <i>Immunohistochemistry (IHC)</i> | 15 |
| <i>Lateral Flow Immunoassay (LFIA)</i> | 15 |
| <i>Radioimmunoassay (RIA)</i> | 15 |
| <i>Western Blotting</i> | 16 |
| IMMUNOASSAY TECHNOLOGY INNOVATIONS AND EMERGING TRENDS | 17 |
| OVERVIEW – INSTRUMENT PLATFORMS | 18 |

| | |
|---|-----------|
| <i>Microtiter Plate-Based Immunoassays and Automation</i> | 18 |
| <i>Automation in Immunoassays</i> | 18 |
| <i>Platform Innovations: Miniaturization, Microfluidics, and Multiplexing</i> | 19 |
| <i>Point-of-Care (POC) and Miniaturized Devices</i> | 19 |
| <i>Lab-on-a-Chip (LOC) and Biochips</i> | 20 |
| <i>Case Example: Veravas VeraBIND Technology</i> | 20 |
| Table 3-2: Selected Immunoassay Technologies | 21 |
| SPECIMEN TYPES | 23 |
| <i>Blood</i> | 23 |
| <i>Urine</i> | 23 |
| <i>Saliva</i> | 24 |
| Table 3-3: Selected Companies with Saliva or Oral-Fluid Collection Devices | 25 |
| CHAPTER 4: MARKET SEGMENT BY SETTING | 26 |
| CENTRALIZED LABORATORIES | 26 |
| Table 4-1: Global Lab-based Immunoassay Market, by Application Segment, 2024 (\$ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others]..... | 27 |
| Figure 4-1: Global Lab-based Immunoassay Market, by Application Segment, 2024 (\$ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others] | 28 |
| Figure 4-2: Global Lab-based Immunoassay Market Distribution, by Application Segment, 2024 (%) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Others] | 29 |
| <i>Companies Marketing to Centralized Laboratories</i> | 29 |
| Table 4-2: Selected Companies Marketing Central Lab-Based Immunoassays Worldwide..... | 30 |
| RAPID AND POINT-OF-CARE TESTING | 34 |
| Table 4-3: Global POC-based Immunoassay Market, by Application Segment, 2024 (\$ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other] | 34 |
| Figure 4-3: Global POC-based Immunoassay Market, by Application Segment, 2024 (\$ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]..... | 35 |
| Figure 4-4: Global POC-based Immunoassay Market Distribution, by Application, 2024 (%) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology, Toxicology, Other]..... | 36 |
| <i>POC Testing in Hospitals</i> | 36 |

| | |
|--|-----------|
| <i>Physician’s Office Laboratories and Clinics</i> | 37 |
| <i>Retail Clinics</i> | 37 |
| <i>Other Professional POC Testing</i> | 38 |
| <i>Self-Testing</i> | 38 |
| <i>Companies Marketing Immunoassay for POC Testing</i> | 41 |
| Table 4-4: Selected Companies Marketing Immunoassay and/or Lateral Flow Tests for POC Worldwide | 41 |
| | |
| CHAPTER 5: IMMUNOASSAY DIAGNOSTIC MARKET ACTIVITY BY APPLICATION | 46 |
| Table 5-1: Immunoassay Market Disease Categories..... | 46 |
| ALLERGY | 47 |
| Figure 5-1: Global Allergy Immunoassay Market, 2024-2029 (\$ million) | 48 |
| Table 5-2: Selected Companies Marketing Immunoassays for Allergy Diagnostics..... | 50 |
| AUTOIMMUNE DISEASE | 51 |
| Figure 5-2: Global Autoimmune Disease Immunoassay Market, 2024-2029 (\$ million) | 52 |
| Table 5-3: Selected Autoantibodies Detected by Autoimmune Immunoassays | 55 |
| CARDIAC MARKERS | 57 |
| Figure 5-3: Global Cardiac Marker Immunoassay Market, 2024-2029 (\$ million)..... | 58 |
| Table 5-4: Selected Cardiac Marker Immunoassays..... | 63 |
| Table 5-5: Selected Cardiac Marker Innovations..... | 64 |
| GENETIC TESTING | 65 |
| Figure 5-4: Global Genetic Immunoassay Market, 2024-2029 (\$ million) | 65 |
| INFECTIOUS DISEASE | 66 |
| Figure 5-5: Global Infectious Disease Immunoassay Market, 2024-2029 (\$ million) | 67 |
| <i>Lab-based Infectious Disease Immunoassays</i> | 68 |
| Table 5-6: Global Lab-based Infectious Disease Immunoassay Sales, 2024 (\$ million) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases] | 68 |
| Figure 5-6: Global Lab-based Infectious Disease Immunoassay Sales, 2024 (\$ million) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases] | 69 |
| Figure 5-7: Global Lab-based Infectious Disease Immunoassay Market Share, 2024 (%) [Blood banking, C. diff, Hepatitis, HIV, MRSA, Respiratory, STD, Staphylococci, TORCH, Other infectious diseases] | 70 |
| <i>Blood Screening</i> | 70 |

| | |
|---|-----|
| Table 5-7: Selected Infectious Disease Immunoassays | 73 |
| Table 5-8: Selected Companies Marketing Immunoassays for Infectious Disease | 75 |
| <i>Hepatitis</i> | 79 |
| <i>Lyme Disease</i> | 81 |
| <i>Rapid and POC Testing</i> | 83 |
| <i>Retroviral</i> | 87 |
| <i>Sexually Transmitted Diseases</i> | 89 |
| <i>ToRCH</i> | 92 |
| <i>COVID-19</i> | 93 |
| Table 5-9: Selected Antigen POC and Home Immunoassay Tests for SARS-CoV-2 | 100 |
| <i>Other Infectious Diseases</i> | 103 |
| METABOLIC DISORDERS AND OTHER HORMONES | 104 |
| Figure 5-8: Global Metabolic and Hormone Disorder Immunoassay Market, 2024-2029 (\$ million) | 104 |
| Table 5-10: Selected Metabolic and Other Hormone Immunoassays | 106 |
| <i>Fertility/Pregnancy/Reproductive Hormones</i> | 107 |
| Table 5-11: Selected Fertility and Reproductive Hormone Immunoassays | 108 |
| <i>Thyroid</i> | 109 |
| Table 5-12: Selected Thyroid Hormone Immunoassays | 110 |
| ONCOLOGY - TUMOR MARKERS | 111 |
| Figure 5-9: Global Oncology Immunoassay Market, 2024-2029 (\$ million) | 111 |
| <i>Lab-based Oncology Immunoassays</i> | 112 |
| Table 5-13: Global Lab-based Tumor Marker Immunoassay Sales, 2024 (\$ million) [AFP, CA-125, CEA, PSA, Others] | 112 |
| Figure 5-10: Global Lab-based Tumor Marker Immunoassay Sales, 2024 (\$ million) [AFP, CA-125, CEA, PSA, Others] | 113 |
| Figure 5-11: Global Lab-based Tumor Marker Immunoassay Market Share, 2024 (%) [AFP, CA-125, CEA, PSA, Others] | 114 |
| Table 5-14: Selected Companies Marketing Immunoassays for Tumor Markers | 117 |
| Table 5-15: Selected Companies Marketing Metabolic Immunoassays | 119 |
| TOXICOLOGY | 121 |
| Figure 5-12: Global Toxicology Marker Immunoassay Market, 2024-2029 (\$ million) | 121 |
| <i>Drugs of Abuse</i> | 122 |
| Table 5-16: Selected Drugs of Abuse Immunoassays | 123 |
| <i>Therapeutic Drug Monitoring</i> | 123 |
| Table 5-17: Selected Therapeutic Drug Monitoring Immunoassays | 124 |

| | |
|---|------------|
| OTHER DISEASE CATEGORIES IN IMMUNOASSAY DISEASE MARKET | 125 |
| Figure 5-13: Other Immunoassay Market, 2024-2029 (\$ million) | 125 |
| Table 5-18: Selected Other Immunoassays | 126 |
| | |
| CHAPTER 6: MARKET OPPORTUNITIES AND ISSUES FOR IMMUNOASSAYS | 127 |
| IMMUNOASSAY MARKET – OVERVIEW | 127 |
| IMMUNOASSAY MARKET DRIVERS AND CHALLENGES | 129 |
| <i>Drivers</i> | 129 |
| NEW AND EMERGING AREAS OF IMMUNOASSAY INNOVATION..... | 131 |
| <i>Gastrointestinal Disorders</i> | 131 |
| Table 6-1: Selected Inflammatory Bowel Disease Test Innovations | 132 |
| <i>Transplant Management</i> | 132 |
| Table 6-2: Selected Immunoassays for Transplant Medicine | 134 |
| <i>Preeclampsia</i> | 134 |
| Table 6-3: Selected Women’s Health Innovations | 136 |
| <i>Alzheimer’s Disease</i> | 136 |
| Table 6-4: Selected Innovations for Alzheimer’s Disease Immunoassays | 140 |
| Table 6-5: Selected Immunoassay Innovations | 141 |
| EMERGING INTERNATIONAL MARKETS | 143 |
| Table 6-6: Selected Companies Outside of North America, Europe, or Japan Marketing Immunoassays | 144 |
| LAB-DEVELOPED TESTS | 146 |
| STAFFING SHORTAGES | 149 |
| OUTLOOK FOR IMMUNOASSAYS..... | 150 |
| | |
| CHAPTER 7: IMMUNOASSAY MARKET ANALYSIS..... | 153 |
| MARKET OVERVIEW AND MARKET SEGMENTS | 153 |
| Table 7-1: Global Immunoassay Market, by Laboratory Setting, 2024-2029 (\$ million) [Lab-based, POC-based] | 153 |
| Figure 7-1: Global Immunoassay Market, by Laboratory Setting, 2024-2029 (\$ million) [Lab-based, POC-based] | 154 |
| Figure 7-2: Global Immunoassay Market Segment Share, by Laboratory Setting, 2024 (%) [Lab-based, POC-based] | 155 |
| <i>Central Lab-based Immunoassay Market</i> | 155 |

| | |
|---|-----|
| Table 7-2: Global Lab-based Immunoassay Market, by Application, 2024-2029 (\$ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Other] | 156 |
| Figure 7-3: Global Lab-based Immunoassay Market, by Application, 2024-2029 (\$ million) [Allergy, Autoimmune, Cardiac Markers, Genetic, Infectious Disease, Metabolic Disorders and Other Hormones, Toxicology, Tumor Markers, Other] | 157 |
| <i>Point of Care/Rapid Test Immunoassays by Disease Category</i> | 157 |
| Table 7-3: Global POC Immunoassay Market Analysis, by Disease Category, 2024 (\$ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other] | 159 |
| Figure 7-4: Global POC Immunoassay Market Analysis, by Disease Category, 2024 (\$ million) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other] | 159 |
| Figure 7-5 Global POC Immunoassay Market Analysis, by Disease Category Market Share, 2024 (%) [Cardiac Markers, Hormone/Fertility, Infectious Disease, Oncology (markers and FOBT), Toxicology, Other]..... | 160 |
| <i>Immunoassay Market by Technology Type</i> | 160 |
| Table 7-4: Global Immunoassay Market, by Technology Segment, 2024-2029 (\$ million) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other] | 161 |
| Figure 7-6: Global Immunoassay Market, by Technology Segment, 2024-2029 (\$ million) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other] | 162 |
| Table 7-5: Global Immunoassay Market Share, by Technology Segment, 2024 (%) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other] | 163 |
| Figure 7-7: Global Immunoassay Market Share, by Technology Segment, 2024 (%) [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other] | 164 |
| COMPETITIVE ANALYSIS | 165 |
| Table 7-6: Global Immunoassay Market Analysis, by Competitor Revenues (\$ million) and Market Share (%), 2024 [Abbott, Becton Dickinson, Bio-Rad, bioMérieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others] | 167 |
| Figure 7-8: Global Immunoassay Market Analysis, by Competitor Revenues (\$ million), 2024 [Abbott, Becton Dickinson, Bio-Rad, bioMérieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others] | 168 |
| Figure 7-9: Global Immunoassay Market Analysis, by Competitor Market Share, 2024 (%) [Abbott, Becton Dickinson, Bio-Rad, bioMérieux, Bruker - CALID, Danaher, DiaSorin, QuidelOrtho, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Others] | 169 |
| IMMUNOASSAY MARKET BY GEOGRAPHIC REGIONS | 170 |
| Table 7-7: Immunoassay Market, by Geographic Region, 2024-2029 (\$ million) [Asia Pacific, Europe, North America, Rest of World] | 170 |
| Figure 7-10: Immunoassay Market, by Geographic Region, 2024-2029 (\$ million) [Asia Pacific, Europe, North America, Rest of World] | 171 |

| | |
|---|------------|
| Figure 7-11: Immunoassay Market Share, by Geographic Region, 2024 (%) [Asia Pacific, Europe, North America, Rest of World] | 172 |
| <i>North America</i> | 172 |
| <i>Europe</i> | 173 |
| Table 7-8: Immunoassay Market, by European Geographic Region, 2024 (\$ million) [France, Germany, Italy, Spain, United Kingdom, Others] | 173 |
| Figure 7-12: Immunoassay Market, by European Geographic Region, 2024 (\$ million) [France, Germany, Italy, Spain, United Kingdom, Others] | 174 |
| Figure 7-13: Immunoassay Market Share, by European Geographic Region, 2024 (%) [France, Germany, Italy, Spain, United Kingdom, Others] | 175 |
| <i>Asia Pacific</i> | 175 |
| Table 7-9: Immunoassay Market, by Asia Pacific Geographic Region, 2024 (\$ million) [China, India, Japan, Others] | 176 |
| Figure 7-14: Immunoassay Market, by Asia Pacific Geographic Region, 2024 (\$ million) [China, India, Japan, Others] | 176 |
| Figure 7-15: Immunoassay Market Share, by Asia Pacific Geographic Region, 2024 (%) [China, India, Japan, Others] | 177 |
| <i>Rest of World</i> | 177 |
| Table 7-10: Immunoassay Market, by Rest of World Geographic Region, 2024 (\$ million) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others] | 178 |
| Figure 7-16: Immunoassay Market, by Rest of World Geographic Region, 2024 (\$ million) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others] | 179 |
| Figure 7-17: Immunoassay Market Share, by Rest of World Geographic Region, 2024 (%) [Brazil, Mexico, Saudi Arabia, South Africa, Turkey, Others] | 180 |
| CHAPTER 8: COMPANY PROFILES | 181 |
| 1 STEP DETECT ASSOCIATES, LLC | 181 |
| Table 8-1: 1-Step Detect Associates Corporate Summary | 181 |
| <i>Company Overview</i> | 181 |
| <i>Products</i> | 181 |
| ABBOTT LABORATORIES | 183 |
| Table 8-2: Abbott Corporate Summary | 183 |
| <i>Company Overview</i> | 183 |
| <i>Products</i> | 184 |
| <i>Performance Review</i> | 186 |
| Table 8-3: Abbott Revenues, 2023-2024 (\$millions) | 187 |

| | |
|--|-----|
| ABINGDON HEALTH, LTD..... | 188 |
| Table 8-4: Abingdon Health Corporate Summary | 188 |
| <i>Company Overview</i> | 188 |
| <i>Products</i> | 189 |
| ACCESS BIO, INC..... | 191 |
| Table 8-5: Access Bio Summary..... | 191 |
| <i>Company Overview</i> | 191 |
| <i>Products</i> | 191 |
| ACCUBIOTECH CO, LTD. | 193 |
| Table 8-6: AccuBioTech Corporate Summary..... | 193 |
| <i>Company Overview</i> | 193 |
| <i>Products</i> | 193 |
| ACON LABORATORIES, INC | 197 |
| Table 8-7: ACON Laboratories Corporate Summary..... | 197 |
| <i>Company Overview</i> | 197 |
| <i>Products</i> | 197 |
| AESKU. DIAGNOSTICS | 200 |
| Table 8-8: AESKU.DIAGNOSTICS Corporate Summary..... | 200 |
| <i>Company Overview</i> | 200 |
| <i>Products</i> | 201 |
| AIDIAN OY | 202 |
| Table 8-9: Aidian Corporate Summary | 202 |
| <i>Company Overview</i> | 202 |
| <i>Products</i> | 202 |
| ALFA SCIENTIFIC DESIGNS, INC | 203 |
| Table 8-10: Alfa Scientific Design | 203 |
| <i>Company Overview</i> | 203 |
| <i>Products</i> | 203 |
| AMERICAN LABORATORY PRODUCTS COMPANY (ALPCO)..... | 206 |
| Table 8-11: American Laboratory Products Corporate Summary | 206 |
| <i>Company Overview</i> | 206 |
| <i>Products</i> | 206 |
| ANBIO BIOTECHNOLOGY | 208 |
| Table 8-12: Anbio Biotechnology Corporate Summary | 208 |

| | |
|--|-----|
| <i>Company Overview</i> | 208 |
| <i>Products</i> | 208 |
| ARKRAY, INC..... | 209 |
| Table 8-13: ARKRAY Corporate Summary | 209 |
| <i>Company Overview</i> | 209 |
| <i>Products</i> | 209 |
| ARLINGTON SCIENTIFIC, INC..... | 211 |
| Table 8-14: Arlington Scientific Corporate Summary | 211 |
| <i>Company Overview</i> | 211 |
| <i>Products</i> | 211 |
| ARTRON LABORATORIES INC. | 214 |
| Table 8-15: Artron Laboratories Corporate Summary..... | 214 |
| <i>Company Overview</i> | 214 |
| <i>Products</i> | 214 |
| ASSOCIATES OF CAPE COD, INC. (ACC)..... | 216 |
| Table 8-16: Associates of Cape Cod Corporate Summary | 216 |
| <i>Company Overview</i> | 216 |
| <i>Products</i> | 216 |
| AUTOBIO DIAGNOSTICS CO., LTD..... | 218 |
| Table 8-17: Autobio Diagnostics Corporate Summary | 218 |
| <i>Company Overview</i> | 218 |
| <i>Products</i> | 219 |
| AVIOQ, INC. | 220 |
| Table 8-18: Avioq Corporate Summary | 220 |
| <i>Company Overview</i> | 220 |
| <i>Products</i> | 220 |
| AWARENESS TECHNOLOGY | 221 |
| Table 8-19: Awareness Technology Corporate Summary..... | 221 |
| <i>Company Overview</i> | 221 |
| <i>Products</i> | 221 |
| BECKMAN COULTER, INC..... | 223 |
| Table 8-20: Beckman Coulter Corporate Summary..... | 223 |
| <i>Company Overview</i> | 223 |
| <i>Products</i> | 224 |

| | |
|--|-----|
| BECTON DICKINSON (BD) | 227 |
| Table 8-21: BD Corporate Summary..... | 227 |
| <i>Company Overview</i> | 227 |
| <i>Products</i> | 228 |
| <i>Company Financials</i> | 230 |
| Table 8-22: BD Corporation Revenue, 2023-2024 (\$ million)..... | 230 |
| BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD..... | 231 |
| Table 8-23: Beijing Wantai Biological Pharmacy Enterprise Corporate Summary..... | 231 |
| <i>Company Overview</i> | 231 |
| <i>Products</i> | 231 |
| BHAT BIO-TECH INDIA PRIVATE LTD. (BBI)..... | 233 |
| Table 8-24: Bhat Bio-Tech India Private Corporate Summary | 233 |
| <i>Company Overview</i> | 233 |
| <i>Products</i> | 233 |
| BIOCHECK, INC. | 235 |
| Table 8-25: BioCheck Corporate Summary..... | 235 |
| <i>Company Overview</i> | 235 |
| <i>Products</i> | 235 |
| BIOHIT OYJ (BIOHIT HEALTHCARE)..... | 237 |
| Table 8-26: Biohit Oyj Corporate Summary..... | 237 |
| <i>Company Overview</i> | 237 |
| <i>Products</i> | 238 |
| BIOLYTICAL LABORATORIES | 239 |
| Table 8-27: bioLytical Laboratories Corporate Summary | 239 |
| <i>Company Overview</i> | 239 |
| <i>Products</i> | 239 |
| BIOMEDOMICS, INC..... | 242 |
| Table 8-28: BioMedomics Corporate Summary | 242 |
| <i>Company Overview</i> | 242 |
| <i>Products</i> | 242 |
| BIOMERICA..... | 244 |
| Table 8-29: Biomerica Summary | 244 |
| <i>Company Overview</i> | 244 |
| <i>Products</i> | 244 |

| | |
|--|-----|
| <i>Company Financials</i> | 246 |
| Table 8-30: Biomerica Corporation Revenue, 2023-2024 (\$ million) | 246 |
| BIOMÉRIEUX SA..... | 247 |
| Table 8-31: bioMérieux SA Corporate Summary | 247 |
| <i>Company Overview</i> | 247 |
| <i>Products</i> | 248 |
| <i>Company Financials</i> | 250 |
| Table 8-32: bioMérieux Revenues, 2023-2024 (€ millions) | 250 |
| BIOPORTO DIAGNOSTICS | 251 |
| Table 8-33: BioPorto Diagnostics Corporate Summary | 251 |
| <i>Company Overview</i> | 251 |
| <i>Products</i> | 251 |
| <i>Company Financials</i> | 252 |
| Table 8-34: BioPorto Diagnostics Revenues, 2023-2024 (DKK millions)..... | 252 |
| BIO-RAD LABORATORIES INC. | 253 |
| Table 8-35: Bio-Rad Labs Corporate Summary..... | 253 |
| <i>Company Overview</i> | 253 |
| <i>Products</i> | 254 |
| <i>Company Financials</i> | 254 |
| Table 8-36: Bio-Rad Corporation Revenue, 2023-2024 (\$ million)..... | 254 |
| BIOSCIENCE (TIANJIN) DIAGNOSTIC TECHNOLOGY CO., LTD. | 255 |
| Table 8-37: Bioscience (Tianjin) Diagnostic Technology Corporate Summary | 255 |
| <i>Company Overview</i> | 255 |
| <i>Products</i> | 255 |
| BIO-TECHNE | 257 |
| Table 8-38: Bio-Techne Corporate Summary | 257 |
| <i>Company Overview</i> | 257 |
| <i>Products</i> | 257 |
| <i>Company Financials</i> | 258 |
| Table 8-39: Bio-Techne, 2023-2024 (\$ million) | 258 |
| BIOTRON DIAGNOSTICS, INC. | 259 |
| Table 8-40: Biotron Diagnostics Corporate Summary | 259 |
| <i>Company Overview</i> | 259 |
| <i>Products</i> | 259 |

| | |
|---|-----|
| BODITECH MED INC. | 261 |
| Table 8-41: Boditech Med Corporate Summary | 261 |
| <i>Company Overview</i> | 261 |
| <i>Products</i> | 262 |
| <i>Performance Review</i> | 264 |
| Table 8-42: Boditech Med Revenues 2023-2024 (KRW billion) | 265 |
| BOSON BIOTECH CO. LTD. | 266 |
| Table 8-43: Boson Biotech Corporate Summary | 266 |
| <i>Company Overview</i> | 266 |
| <i>Products</i> | 266 |
| BUHLMANN LABORATORIES AG | 267 |
| Table 8-44: BUHLMANN Laboratories Summary | 267 |
| <i>Company Overview</i> | 267 |
| <i>Products</i> | 267 |
| CERTEST BIOTEC | 269 |
| Table 8-45: Certest Biotec Summary | 269 |
| <i>Company Overview</i> | 269 |
| <i>Products</i> | 269 |
| CHEMBIO DIAGNOSTIC SYSTEMS, INC. | 271 |
| Table 8-46: Chembio Diagnostic Corporate Summary | 271 |
| <i>Company Overview</i> | 271 |
| <i>Products</i> | 272 |
| CLARITY DIAGNOSTICS, LLC | 276 |
| Table 8-47: Clarity Diagnostics Corporate Summary | 276 |
| <i>Company Overview</i> | 276 |
| <i>Products</i> | 276 |
| CONFIRM BIOSCIENCES | 278 |
| Table 8-48: Confirm Biosciences Corporate Summary | 278 |
| <i>Company Overview</i> | 278 |
| <i>Products</i> | 278 |
| CTK BIOTECH, INC. | 281 |
| Table 8-49: CTK Biotech Corporate Summary | 281 |
| <i>Company Overview</i> | 281 |
| <i>Products</i> | 281 |

| | |
|---|-----|
| DIAGENICS GROUP SE | 283 |
| Table 8-50: Diagenics Group Corporate Summary | 283 |
| <i>Company Overview</i> | 283 |
| <i>Products</i> | 283 |
| DIALAB GMBH | 285 |
| Table 8-51: DIALAB Summary | 285 |
| <i>Company Overview</i> | 285 |
| <i>Products</i> | 285 |
| DIAMETRA | 287 |
| Table 8-52: Diametra Corporate Summary | 287 |
| <i>Company Overview</i> | 287 |
| <i>Products</i> | 287 |
| DIASORIN S.P.A. | 289 |
| Table 8-53: DiaSorin Corporate Summary | 289 |
| <i>Company Overview</i> | 289 |
| <i>Products</i> | 290 |
| <i>Company Financials</i> | 291 |
| Table 8-54: DiaSorin 2023-2024 (€ thousand) | 291 |
| DIASOURCE IMMUNOASSAYS SA | 292 |
| Table 8-55: DiaSource ImmunoAssays Corporate Summary | 292 |
| <i>Company Overview</i> | 292 |
| <i>Products</i> | 292 |
| DIASYS DIAGNOSTIC SYSTEMS GMBH (MINDRAY) | 294 |
| Table 8-56: DiaSys Diagnostic Systems Corporate Summary | 294 |
| <i>Company Overview</i> | 294 |
| <i>Products</i> | 294 |
| DIAZYME LABORATORIES, INC. | 296 |
| Table 8-57: Diazyme Laboratories Corporate Summary | 296 |
| <i>Company Overview</i> | 296 |
| <i>Products</i> | 296 |
| DR. FOOKE-ACHTERRATH LABORATORIEN GMBH | 298 |
| Table 8-58: Dr. Fooke-Achterrath Laboratorien Corporate Summary | 298 |
| <i>Company Overview</i> | 298 |
| <i>Products</i> | 298 |

| | |
|--|-----|
| EIKEN CHEMICAL CO LTD. | 300 |
| Table 8-59: Eiken Chemical Corporate Summary | 300 |
| <i>Company Overview</i> | 300 |
| <i>Products</i> | 301 |
| <i>Performance Review</i> | 302 |
| Table 8-60: Eiken Chemical Revenues, 2023-2024 (million yen) | 302 |
| EKF DIAGNOSTICS HOLDINGS PLC | 303 |
| Table 8-61: EKF Diagnostics Corporate Summary | 303 |
| <i>Company Overview</i> | 303 |
| <i>Products</i> | 304 |
| ELITTECHGROUP S.A.S. | 306 |
| Table 8-62: ELITechGroup Corporate Summary | 306 |
| <i>Company Overview</i> | 306 |
| <i>Products</i> | 307 |
| EUROBIO SCIENTIFIC..... | 309 |
| Table 8-63: Eurobio Scientific Corporate Summary | 309 |
| <i>Company Overview</i> | 309 |
| <i>Products</i> | 310 |
| EUROSPITAL SPA | 312 |
| Table 8-64: Eurospital Summary | 312 |
| <i>Company Overview</i> | 312 |
| <i>Products</i> | 312 |
| EY LABORATORIES | 314 |
| Table 8-65: EY Laboratories Summary..... | 314 |
| <i>Company Overview</i> | 314 |
| <i>Products</i> | 314 |
| FUJIREBIO-US, INC. | 315 |
| Table 8-66: Fujirebio Corporate Summary | 315 |
| <i>Company Overview</i> | 315 |
| <i>Products</i> | 317 |
| GENBIO..... | 319 |
| Table 8-67: GenBio Corporate Summary..... | 319 |
| <i>Company Overview</i> | 319 |
| <i>Products</i> | 319 |

| | |
|--|-----|
| GOLD STANDARD DIAGNOSTICS..... | 321 |
| Table 8-68: Gold Standard Diagnostics Corporate Summary | 321 |
| <i>Company Overview</i> | 321 |
| <i>Products</i> | 321 |
| GRIFOLS INTERNATIONAL S.A..... | 323 |
| Table 8-69: Grifols International S.A. Corporate Summary | 323 |
| <i>Company Overview</i> | 323 |
| <i>Products</i> | 324 |
| <i>Company Financials</i> | 324 |
| Table 8-70: Grifols Revenue, 2023-2024 (€ million) | 324 |
| HEMOSURE, INC. | 325 |
| Table 8-71: Hemosure Corporate Summary..... | 325 |
| <i>Company Overview</i> | 325 |
| <i>Products</i> | 325 |
| HYCOR BIOMEDICAL, INC. | 327 |
| Table 8-72: HYCOR Biomedical Corporate Summary | 327 |
| <i>Company Overview</i> | 327 |
| <i>Products</i> | 327 |
| IMMUNO-MYCOLOGICS, INC. | 328 |
| Table 8-73: Immuno-Mycologics Corporate Summary..... | 328 |
| <i>Company Overview</i> | 328 |
| <i>Products</i> | 328 |
| IMMUNOSCIENCES LAB, INC..... | 329 |
| Table 8-74: Immunosciences Lab Corporate Summary | 329 |
| <i>Company Overview</i> | 329 |
| <i>Products</i> | 329 |
| IMMUNOSTICS, INC..... | 330 |
| Table 8-75: Immunostics Corporate Summary..... | 330 |
| <i>Company Overview</i> | 330 |
| <i>Products</i> | 330 |
| INBIOS INTERNATIONAL, INC..... | 332 |
| Table 8-76: InBios Corporate Summary..... | 332 |
| <i>Company Overview</i> | 332 |
| <i>Products</i> | 332 |

| | |
|--|-----|
| JAL INNOVATION PTE LTD | 334 |
| Table 8-77: JAL Innovation Corporate Summary | 334 |
| <i>Company Overview</i> | 334 |
| <i>Products</i> | 334 |
| JANT PHARMACAL CORPORATION | 336 |
| Table 8-78: Jant Pharmacal Summary | 336 |
| <i>Company Overview</i> | 336 |
| <i>Products</i> | 336 |
| J. MITRA & CO PVT. LTD | 338 |
| Table 8-79: J Mitra Corporate Summary | 338 |
| <i>Company Overview</i> | 338 |
| <i>Products</i> | 338 |
| KRONUS | 340 |
| Table 8-80: KRONUS Corporate Summary | 340 |
| <i>Company Overview</i> | 340 |
| <i>Products</i> | 340 |
| KYPHA | 342 |
| Table 8-81: Kypha Corporate Summary | 342 |
| <i>Company Overview</i> | 342 |
| <i>Products</i> | 342 |
| LABSYSTEMS DIAGNOSTICS OY | 343 |
| Table 8-82: Labsystems Diagnostics Corporate Summary | 343 |
| <i>Company Overview</i> | 343 |
| <i>Products</i> | 343 |
| LAMDAGEN CORPORATION | 345 |
| Table 8-83: LamdaGen Corporate Summary | 345 |
| <i>Company Overview</i> | 345 |
| <i>Products</i> | 345 |
| LIFESIGN, LLC | 347 |
| Table 8-84: LifeSign Summary | 347 |
| <i>Company Overview</i> | 347 |
| <i>Products</i> | 347 |
| MACHEREY-NAGEL GMBH & CO. KG | 349 |
| Table 8-85: Macherey-Nagel Corporate Summary | 349 |

| | |
|--|-----|
| <i>Company Overview</i> | 349 |
| <i>Products</i> | 349 |
| MEDIX BIOCHEMICA..... | 351 |
| Table 8-86: Medix Biochemica Summary | 351 |
| <i>Company Overview</i> | 351 |
| <i>Products</i> | 352 |
| MEDMIRA, INC..... | 354 |
| Table 8-87: MedMira Corporate Summary | 354 |
| <i>Company Overview</i> | 354 |
| <i>Products</i> | 355 |
| <i>Performance Review</i> | 358 |
| Table 8-88: MedMira, Revenues 2023-2024 (\$ thousands) | 358 |
| MERCODIA AB..... | 359 |
| Table 8-89: Mercodia AB Summary | 359 |
| <i>Company Overview</i> | 359 |
| <i>Products</i> | 359 |
| MERIDIAN BIOSCIENCE, INC | 361 |
| Table 8-90: Meridian BioScience Corporate Summary..... | 361 |
| <i>Company Overview</i> | 361 |
| <i>Products</i> | 362 |
| MONOBIND, INC | 365 |
| Table 8-91: Monobind Corporate Summary..... | 365 |
| <i>Company Overview</i> | 365 |
| <i>Products</i> | 365 |
| NANO-DITECH CORPORATION..... | 367 |
| Table 8-92: Nano-Ditech Corporate Summary | 367 |
| <i>Company Overview</i> | 367 |
| <i>Products</i> | 367 |
| NEXUS DX INC | 369 |
| Table 8-93: Nexus Dx Corporate Summary | 369 |
| <i>Company Overview</i> | 369 |
| <i>Products</i> | 369 |
| NOVA BIOMEDICAL, CORP..... | 371 |
| Table 8-94: Nova Biomedical Corporate Summary | 371 |

| | |
|--|-----|
| <i>Company Overview</i> | 371 |
| <i>Products</i> | 372 |
| OASIS DIAGNOSTICS CORPORATION | 375 |
| Table 8-95: Oasis Diagnostics Corporate Summary | 375 |
| <i>Company Overview</i> | 375 |
| <i>Products</i> | 375 |
| OPERON | 377 |
| Table 8-96: Operon Corporate Summary | 377 |
| <i>Company Overview</i> | 377 |
| <i>Products</i> | 377 |
| OPKO HEALTH, INC..... | 379 |
| Table 8-97: OPKO Health Corporate Summary | 379 |
| <i>Company Overview</i> | 379 |
| <i>Products</i> | 380 |
| <i>Performance Review</i> | 380 |
| Table 8-98: OPKO Health Revenues, 2023-2024 (\$ million) | 381 |
| ORASURE TECHNOLOGIES, INC..... | 382 |
| Table 8-99: OraSure Technologies Corporate Summary | 382 |
| <i>Company Overview</i> | 382 |
| <i>Products</i> | 384 |
| <i>Performance Review</i> | 386 |
| Table 8-100: OraSure Revenues, 2023-2024 (\$ million) | 386 |
| PIXCELL MEDICAL TECHNOLOGIES..... | 387 |
| Table 8-101: PixCell Corporate Summary | 387 |
| <i>Company Overview</i> | 387 |
| <i>Products</i> | 387 |
| POLYMEDCO, INC | 389 |
| Table 8-102: Polymedco Corporate Summary..... | 389 |
| <i>Company Overview</i> | 389 |
| <i>Products</i> | 389 |
| PRECISION BIOSENSOR..... | 391 |
| Table 8-103: Precision Biosensor Corporate Summary | 391 |
| <i>Company Overview</i> | 391 |
| <i>Products</i> | 391 |

| | |
|---|-----|
| PREVENTIS GMBH | 393 |
| Table 8-104: Preventis Corporate Summary | 393 |
| <i>Company Overview</i> | 393 |
| <i>Products</i> | 393 |
| PRINCETON BIOMEDITECH CORPORATION | 395 |
| Table 8-105: Princeton Biomeditech Corporate Summary..... | 395 |
| <i>Company Overview</i> | 395 |
| <i>Products</i> | 395 |
| PTS DIAGNOSTICS | 397 |
| Table 8-106: PTS Corporate Summary..... | 397 |
| <i>Company Overview</i> | 397 |
| <i>Products</i> | 398 |
| QUALIGEN, INC. | 400 |
| Table 8-107: Qualigen Corporate Summary | 400 |
| <i>Company Overview</i> | 400 |
| <i>Products</i> | 400 |
| QUANTERIX CORPORATION..... | 401 |
| Table 8-108: Quanterix Corporate Summary | 401 |
| <i>Company Overview</i> | 401 |
| <i>Products</i> | 401 |
| QUIDELORTHO CORPORATION | 403 |
| Table 8-109: QuidelOrtho Corporate Summary | 403 |
| <i>Company Overview</i> | 403 |
| <i>Products</i> | 403 |
| <i>Performance Review</i> | 407 |
| Table 8-110: QuidelOrtho Revenues, 2023-2024 (\$ million) | 407 |
| RADIOMETER MEDICAL A/S | 408 |
| Table 8-111: Radiometer Medical Corporate Summary..... | 408 |
| <i>Company Overview</i> | 408 |
| <i>Products</i> | 409 |
| RESPONSE BIOMEDICAL CORP | 411 |
| Table 8-112: Response Biomedical Corporate Summary | 411 |
| <i>Company Overview</i> | 411 |
| <i>Products</i> | 411 |

| | |
|---|-----|
| RESZON DIAGNOSTICS INTERNATIONAL SDN. BHD..... | 413 |
| Table 8-113: Reszon Diagnostics Corporate Summary..... | 413 |
| <i>Company Overview</i> | 413 |
| <i>Products</i> | 413 |
| REVVITY..... | 415 |
| Table 8-114: Revvity Corporate Summary..... | 415 |
| <i>Company Overview</i> | 415 |
| <i>Products</i> | 416 |
| <i>Performance Review</i> | 417 |
| Table 8-115: Revvity Revenues, 2023-2024 (\$ million) | 417 |
| ROCHE DIAGNOSTIC CORPORATION..... | 418 |
| Table 8-116: Roche Corporate Summary | 418 |
| <i>Company Overview</i> | 418 |
| <i>Products</i> | 419 |
| <i>Performance Review</i> | 421 |
| Table 8-117: Roche Diagnostics Revenue, 2023-2024 (CHF millions)..... | 422 |
| SAVYON DIAGNOSTICS LTD. | 423 |
| Table 8-118: Savyon Diagnostics Summary..... | 423 |
| <i>Company Overview</i> | 423 |
| <i>Products</i> | 423 |
| SEKISUI DIAGNOSTICS LLC..... | 425 |
| Table 8-119: Sekisui Diagnostics Corporate Summary | 425 |
| <i>Company Overview</i> | 425 |
| <i>Products</i> | 425 |
| SIEMENS HEALTHINEERS | 427 |
| Table 8-120: Siemens Healthineers Corporate Summary..... | 427 |
| <i>Company Overview</i> | 427 |
| <i>Products</i> | 428 |
| <i>Performance Review</i> | 432 |
| Table 8-121: Siemens Healthineers Revenue, 2023-2024 (€ millions) | 432 |
| SYNTRON BIORESEARCH, INC. | 433 |
| Table 8-122: Syntron Bioresearch Corporate Summary..... | 433 |
| <i>Company Overview</i> | 433 |
| <i>Products</i> | 433 |

| | |
|--|-----|
| SYSMEX CORPORATION | 435 |
| Table 8-123: Sysmex Corporate Summary | 435 |
| <i>Company Overview</i> | 435 |
| <i>Products</i> | 436 |
| <i>Performance Review</i> | 438 |
| Table 8-124: Sysmex Revenues, 2023-2024 (billion yen) | 438 |
| TECHLAB, INC. | 439 |
| Table 8-125: TECHLAB Corporate Summary | 439 |
| <i>Company Overview</i> | 439 |
| <i>Products</i> | 439 |
| TECO DIAGNOSTICS | 441 |
| Table 8-126: Teco Diagnostics Corporate Summary | 441 |
| <i>Company Overview</i> | 441 |
| <i>Products</i> | 441 |
| THERMO FISHER SCIENTIFIC, INC | 443 |
| Table 8-127: Thermo Fisher Scientific Corporate Summary | 443 |
| <i>Company Overview</i> | 443 |
| <i>Products</i> | 445 |
| <i>Company Financials</i> | 447 |
| Table 8-128: Thermo Fisher Scientific Revenues, 2023-2024 (\$ million) | 447 |
| TOSOH BIOSCIENCE, INC. | 448 |
| Table 8-129: Tosoh Bioscience Corporate Summary | 448 |
| <i>Company Overview</i> | 448 |
| <i>Products</i> | 448 |
| <i>Company Financials</i> | 449 |
| Table 8-130: Tosoh Corporation Revenue, 2023-2024 (billion yen) | 449 |
| TRINITY BIOTECH PLC | 450 |
| Table 8-131: Trinity Biotech Corporate Summary | 450 |
| <i>Company Overview</i> | 450 |
| <i>Products</i> | 451 |
| TRUE DIAGNOSTICS | 454 |
| Table 8-132: True Diagnostics Corporate Summary | 454 |
| <i>Company Overview</i> | 454 |
| <i>Products</i> | 454 |

| | |
|---|-----|
| VEDALAB | 455 |
| Table 8-133: VedaLab Corporate Summary..... | 455 |
| <i>Company Overview</i> | 455 |
| <i>Products</i> | 455 |
| VIRCELL | 457 |
| Table 8-134: Vircell Corporate Summary | 457 |
| <i>Company Overview</i> | 457 |
| <i>Products</i> | 457 |
| WAMA DIAGNOSTICA | 459 |
| Table 8-135: WAMA Diagnostica Corporate Summary | 459 |
| <i>Company Overview</i> | 459 |
| <i>Products</i> | 459 |
| WERFEN GROUP | 461 |
| Table 8-136: Werfen Group Corporate Summary | 461 |
| <i>Company Overview</i> | 461 |
| <i>Products</i> | 462 |
| ZEUS SCIENTIFIC, INC..... | 465 |
| Table 8-137: Zeus Scientific Corporate Summary..... | 465 |
| <i>Company Overview</i> | 465 |
| <i>Products</i> | 465 |

SAMPLE Chapter

Scope and Methodology

The global market for immunoassays is presented in U.S. dollars for the period from 2024 to 2029. Market analyses in this report cover worldwide immunoassay markets, ranging from high-throughput instruments used in centralized core laboratories to manual lateral flow and other point-of-care (POC) immunoassays. The report also includes immunochromatographic or lateral flow rapid tests.

There is a focus on developed regions—namely North America, Western Europe, and developed Asia-Pacific markets. Immunoassays, including lateral flow POC tests, play a critical role in expanding healthcare access to areas lacking the infrastructure for traditional, centralized diagnostics.

Market data in this report are based on manufacturer revenues, not retail pricing or reimbursement payments. The dollar value of each market segment is generally proportional to the number of tests performed, as the cost of instrumentation is typically embedded in the per-test price.

A comprehensive combination of primary and secondary research was employed to ensure accuracy, depth, and relevance in assessing current market conditions and trends. The research process involved multiple phases to gather, verify, and analyze information from a wide range of credible sources.

Information was collected through an extensive review of publicly available and proprietary databases, including industry reports, company literature, regulatory filings, investment and equity research, and medical and business journals. This helped establish context, identify market participants, and assess competitive positioning.

To validate and expand upon secondary findings, Kalorama Information conducted over 30 in-depth interviews with key industry stakeholders, including executives, product managers, marketing directors, consultants, healthcare providers, and government officials. Telephone interviews and email correspondence were the primary modes of communication, offering qualitative insights into market dynamics, customer behavior, and emerging trends.

Additional outreach to company representatives provided specific data points on revenue, market share, and product performance. These interactions were essential for corroborating financial data and understanding business strategies at both the segment and product levels. All data were cross-verified with multiple sources to ensure consistency and reliability. Where possible, estimates were triangulated using a combination of publicly disclosed information, proprietary databases, and expert interviews.

Market sizing and forecast models were built using historical data, growth trends, and assumptions informed by primary research. The base year for the data is 2024, and compound annual growth rates (CAGRs) are provided for the 2024–2029 period for each segment analyzed. Research findings support a comprehensive competitive analysis for the year 2024. Forecasts for 2025–2029 are primarily based on demographic trends, technological innovations, and global market expansion.

It is important to note that the market areas covered in this report are evolving rapidly. Some company and technology information may become outdated by the time of publication. Kalorama is aware of these developments; however, the major themes, key players, and core issues remain relevant and unchanged.

Market Overview and Market Segments

The immunoassay market is a substantial and well-established sector, with sales reaching **\$XX Million** in 2024. It comprises two major segments:

- Lab-based immunoassays, performed in centralized laboratories for clinical purposes such as screening, diagnosis, and patient monitoring.
- Point-of-care (POC) or rapid immunoassays, also used for clinical indications but designed for faster, decentralized testing.


SAMPLE: Global Immunoassay Market, by Laboratory Setting, 2024-2029 (\$ million)

| Laboratory Setting | 2024 | 2029 | CAGR 2024-2029 |
|--------------------|-------------------|-------------------|----------------|
| Lab-based | XX million | XX million | XX% |
| POC-based | XX million | XX million | XX% |
| Total | XX million | XX million | XX% |

Source: Kalorama Information

SAMPLE: Global Immunoassay Market, by Laboratory Setting, 2024-2029 (\$ million)

Global Immunoassay Market, 2024-2029 (\$ million)



Source: Kalorama Information

Central Lab-based Immunoassay Market

Central lab-based immunoassays represent, by far, the largest segment of the immunoassay market, accounting for **XX%** of the total market in 2024. However, this segment's share is gradually shrinking due to the more rapid growth of the point-of-care (POC) or rapid test segment.

The largest subsegment within the central lab-based immunoassay market is infectious diseases, which generated **XX million** in sales in 2024—representing **XX%** of the total segment. The next two largest subsegments are metabolic disorders and other hormones, and tumor markers, accounting for **XX%** and **XX%** of the market, respectively. The metabolic disorders and other hormones category (**XX%** of the lab-based immunoassay market) actually comprises a group of disease indications. Other disease indications represent much

smaller portions of the market. Cardiac markers, for example, captured **XX%** of the total market share in 2024.

The genetic lab-based immunoassay market is the fastest-growing application area, with a projected compound annual growth rate (CAGR) of **XX%** from 2024 to 2029.


SAMPLE: Global Lab-based Immunoassay Market, by Application, 2024-2029 (\$ million)

| Segment | 2024 | 2029 | CAGR 2024-2029 |
|--|-------------------|-------------------|----------------|
| Infectious Disease | XX million | XX million | XX% |
| Tumor Markers | XX million | XX million | XX% |
| Metabolic Disorders and Other Hormones | XX million | XX million | XX% |
| Cardiac Markers | XX million | XX million | XX% |
| Genetic | XX million | XX million | XX% |
| Toxicology | XX million | XX million | XX% |
| Autoimmune | XX million | XX million | XX% |
| Allergy | XX million | XX million | XX% |
| Other | XX million | XX million | XX% |
| Total | XX million | XX million | XX% |

Source: Kalorama Information

SAMPLE: Global Lab-based Immunoassay Market, by Application, 2024-2029 (\$ million)

Global Lab-based Immunoassay Market, by Application, 2024-2029 (\$ million)



Source: Kalorama Information

Point of Care/Rapid Test Immunoassays by Disease Category

The two largest segments of the point-of-care (POC)/rapid testing market are infectious disease tests and fertility tests, accounting for **XX%** and **XX%**, respectively, of the total POC/rapid test immunoassay market.

The goal of POC infectious disease testing is to detect pathogens in humans and determine the most appropriate course of antimicrobial treatment. While the threat of infectious diseases is often associated with developing countries, they are also a major cause of morbidity and mortality in developed regions such as Europe and the United States. Various factors—including emerging infectious diseases, mass migration, global travel, antibiotic misuse, and co-infections—underscore the need for continuous global efforts and innovative research to combat these expanding threats.

Lab-based infectious disease tests often fail to meet the urgent needs of mass screening and diagnostic programs required by public health professionals and clinicians in both developing and developed countries. As a result, there is growing demand for reliable rapid tests for infectious diseases. These tests enable earlier diagnosis and treatment, reduce healthcare costs, and help avoid unnecessary quarantines and delays. Studies have shown that many individuals seen in clinics do not return to receive their lab test results and therefore remain untreated if they test positive.

Infectious disease testing will continue to be a key driver of diagnostic testing, as new pathogen strains emerge annually—such as seasonal influenza, H1N1, Lyme disease, and West Nile virus. Additionally, hospital-acquired infections like Methicillin-resistant *Staphylococcus aureus* (MRSA) necessitate increased testing.

Hormone/fertility testing represents a market valued at **XX million** in 2024. This category includes POC tests for pregnancy, ovulation, and menopause. These tests are frequently purchased and performed by consumers, making this a significant over-the-counter (OTC)/self-test segment.

POC/rapid cardiac tests are critical in emergency settings, such as when patients present with symptoms of a potential heart attack. Available cardiac markers assist physicians in diagnosing, prognosing, and managing the risk of cardiovascular diseases such as heart failure and myocardial infarction. However, there is an ongoing effort to identify additional cardiac markers that can detect earlier stages of myocardial infarction, thereby improving treatment outcomes and saving lives. POC/rapid cardiac marker revenues totaled **XX million** in 2024.


SAMPLE: Global POC Immunoassay Market Analysis, by Disease Category, 2024 (\$ million)

| Product Type | Revenue Estimates | Total Market Share |
|-----------------------------|-------------------|--------------------|
| Infectious Disease | XX million | XX% |
| Hormone/Fertility | XX million | XX% |
| Cardiac Markers | XX million | XX% |
| Toxicology | XX million | XX% |
| Oncology (markers and FOBT) | XX million | XX% |
| Other | XX million | XX% |
| Total | XX million | XX% |

Source: Kalorama Information

SAMPLE: Global POC Immunoassay Market Analysis, by Disease Category, 2024 (\$ million)

Global POC Immunoassay Market, by Disease Category, 2024 (\$ million)



Source: Kalorama Information

Immunoassay Market by Technology Type

The immunoassay market by technology is segmented into:

- Chemiluminescent immunoassay (CLIA)
- Enzyme-linked immunosorbent assay (ELISA)
- Fluorescence immunoassay (FIA)
- Immunohistochemistry (IHC)
- Lateral flow immunoassay (LFIA)
- Radioimmunoassay (RIA)
- Others

The chemiluminescent immunoassay (CLIA) segment captured **XX%** of the global immunoassay market by technology. CLIA technology is poised for further development. In the coming years, new and more efficient analytical methods based on the principles of chemiluminescence are expected to be introduced into diagnostics at steadily decreasing costs. This transformation will align antibody diagnostics with already established biochemistry and immunoassay methods, offering noticeable advantages in both diagnostic accuracy and efficiency.

ELISA was the second most utilized technology, accounting for **XX%** in 2024. The integration of artificial intelligence (AI) is renewing interest in ELISA immunoassays. ELISA has long been a cornerstone of diagnostics, enabling the identification and quantification of biomolecules critical for disease diagnosis. However, ELISA immunoassays have faced challenges due to labor-intensive protocols and susceptibility to errors, which have impacted reliability and speed. The incorporation of AI has enhanced both speed and precision, ushering in a new era for ELISA-based diagnostics.


SAMPLE: Global Immunoassay Market, by Technology Segment, 2024-2029 (\$ million)

| Segment | 2024 | 2029 | CAGR 2024-2029 |
|---|-------------------|-------------------|----------------|
| Chemiluminescent immunoassay (CLIA) | XX million | XX million | XX% |
| Enzyme-linked immunosorbent assay (ELISA) | XX million | XX million | XX% |
| Lateral flow immunoassay (LFIA) | XX million | XX million | XX% |
| Fluorescence immunoassay (FIA) | XX million | XX million | XX% |
| Immunohistochemistry (IHC) | XX million | XX million | XX% |
| Radioimmunoassay (RIA) | XX million | XX million | XX% |
| Other | XX million | XX million | XX% |
| Total | XX million | XX million | XX% |

Source: Kalorama Information

SAMPLE: Global Immunoassay Market, by Technology Segment, 2024-2029 (\$ million)
 [CLIA, ELISA, FIA, IHC, LFIA, RIA, Other]

Global Immunoassay Market, by Technology Segment, 2024-2029 (\$ million)



Source: Kalorama Information

SAMPLE: Global Immunoassay Market Share, by Technology Segment, 2024 (%)

| Segment | 2024 |
|---|------------|
| Chemiluminescent immunoassay (CLIA) | XX% |
| Enzyme-linked immunosorbent assay (ELISA) | XX% |
| Lateral flow immunoassay (LFIA) | XX% |
| Fluorescence immunoassay (FIA) | XX% |
| Immunohistochemistry (IHC) | XX% |
| Radioimmunoassay (RIA) | XX% |
| Other | XX% |
| Total | XX% |

Source: Kalorama Information

Competitive Analysis

The immunoassay market as a whole demonstrated growth in 2024. However, COVID-19 testing continued to influence certain areas of the competitive landscape. The global immunoassay market has been dominated by three leading IVD companies: Roche, Abbott Diagnostics, and Siemens Healthineers.

Roche secured the leading position, accounting for **XX%** of the global market share. Over the past few years, Roche Diagnostics has aggressively expanded its presence, displacing Abbott as the market leader. Roche has excelled in infectious disease testing, as well as in diagnostics for women's health, sepsis, vitamin D, and various cancer markers. In 2024, global immunoassay revenues reached **XX million** (or **XX billion**).

Abbott held the second-largest market share at **XX%**. Its strength lies in a broad menu of tests and assay systems, along with a dominant position in the global infectious disease testing market—capturing at least **XX%** when including its point-of-care (POC) offerings, particularly for hepatitis and HIV, outside the United States. Key emerging markets include India, Russia, Brazil, and China. Abbott has also expanded its portfolio with tests such as the Galectin-3 assay (for assessing prognosis in chronic heart failure) and the HbA1c test. The acquisition of Alere significantly strengthened Abbott's position in POC and rapid testing, building on an already substantial presence in the IVD immunoassay market.

Siemens Healthineers, the third-largest provider, captured **XX%** of the market in 2024. Its Immulite product line, a dedicated immunoanalyzer, has been automated and complemented by the ADVIA Centaur Immunoassay Systems—originally developed by Bayer Diagnostics—focusing on chemiluminescence testing.

Danaher's Beckman Coulter secured a **XX%** market share. Its Access and Synchron systems offer a wide and continuously expanding test menu. Beckman Coulter's immunoassay portfolio includes over 60 tests for cancer detection, cardiac disease, thyroid function, reproductive endocrinology, and women's health. The company continues to introduce novel and proprietary tests, including those for inhibin A, High Mobility Group Box 1 (septic shock), erythropoietin, cPAPP (plaque instability marker), placental growth factor (PIGF), soluble fms-like tyrosine kinase 1 (sFlt-1), soluble CD40 ligand (sCD40L), preeclampsia, fertility hormones, cardiovascular disease, autoimmune and inflammatory diseases, cytokines, and prenatal screening.

bioMérieux offers an immunoassay product line with over 130 products, including rapid single-dose tests (VIKIA), high-throughput microplate processors (DAVINCI), and automated multiparametric analyzers (VIDAS, miniVIDAS, and VIDIA). The VIDAS range includes 99 tests covering bacterial, viral, and parasitic identification, antibody detection, protein markers for cardiovascular diseases and cancers, inflammatory responses, and hormonal dysfunction. In 2014, bioMérieux launched the FDA-cleared and CE-marked VIDAS *C. difficile* GDH assay, a fully automated and cost-effective solution for *C. difficile* diagnosis and infection control.

Thermo Fisher Scientific accounted for **XX%** of the total market. It offers a broad range of diagnostic test kits, reagents, culture media, instruments, and related products for healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

DiaSorin also held a **XX%** market share, offering a menu of over 122 assays across various areas, including bone and mineral metabolism, thyroid function, reproductive endocrinology, anemia, cardiac markers, autoimmunity, tumor markers, hypertension, adrenal function, growth, diabetes, sepsis, viral hepatitis and HIV, Treponema, EBV, ToRCH, Borrelia, VZV, Mycoplasma, measles and mumps, chlamydia, and stool diagnostics. Its LIAISON and LIAISON XL platforms are based on chemiluminescent immunoassay (CLIA) technology.

Over 100 other companies compete for the remaining **XX%** of the market. Many smaller players offer ELISA-based tests for local markets, while niche players such as Fujirebio, Bryker-CALID, QuidelOrtho, Bio-Rad, and Revvity maintain strong positions in specialized segments.

Mindray launched two new CLIA stand-alone analyzers for mid-volume laboratories: the CL-9000i for small labs and the CL-6000i for mid-sized labs, both offering high throughput. Additional systems include the SAL 6000 modular system for fast throughput and integration, and the SAL 9000 modular system, which combines the BS-2000 Chemistry Analyzer with the CL-6000i Chemiluminescence Immunoassay Analyzer for high-throughput chemistry and immunoassay testing.


SAMPLE: Global Immunoassay Market, by Competitor Revenues (\$ million) and Market Share (%), 2024

| Supplier | Revenue Estimates | Market Share |
|--------------------------|-------------------|--------------|
| Roche | XX million | XX% |
| Abbott | XX million | XX% |
| Siemens Healthineers | XX million | XX% |
| QuidelOrtho | XX million | XX% |
| Danaher | XX million | XX% |
| Becton Dickinson | XX million | XX% |
| bioMérieux | XX million | XX% |
| Thermo Fisher Scientific | XX million | XX% |
| Bruker - CALID | XX million | XX% |
| DiaSorin | XX million | XX% |
| Revvity | XX million | XX% |
| Bio-Rad | XX million | XX% |
| Others | XX million | XX% |
| Total | XX million | XX% |

Source: Kalorama Information

SAMPLE: Global Immunoassay Market Analysis, by Competitor Revenues (\$ million), 2024

Global Immunoassay Market Analysis, by Competitor Revenues (\$ million)



Source: Kalorama Information

Immunoassay Market by Geographic Regions

The global immunoassay market is divided into four geographic regions:

- North America
- Europe
- Asia Pacific
- Rest of the World

North America is the largest region in the immunoassay market, while Asia Pacific is the fastest-growing. All regions are expected to demonstrate positive growth during the forecast period from 2024 to 2029.


SAMPLE: Immunoassay Market, by Geographic Region, 2024-2029 (\$ million)

| Segment | 2024 | 2029 | CAGR 2024-2029 |
|---------------|------------|-------------------|----------------|
| North America | XX% | XX million | XX% |
| Europe | XX% | XX million | XX% |
| Asia Pacific | XX% | XX million | XX% |
| Rest of World | XX% | XX million | XX% |
| Total | XX% | XX million | XX% |

Source: Kalorama Information

SAMPLE: Immunoassay Market, by Geographic Region, 2024-2029 (\$ million)

Immunoassay Market, by Geographic Region, 2024-2029 (\$ million)



Source: Kalorama Information